Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Adjuvant therapy of malignant melanoma: is there a choice?
Autore:
Retsas, S;
Indirizzi:
Charing Cross Hosp, Dept Med Oncol, Melanoma Unit, London W6 8RF, England Charing Cross Hosp London England W6 8RF ma Unit, London W6 8RF, England
Titolo Testata:
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
fascicolo: 2, volume: 40, anno: 2001,
pagine: 187 - 193
SICI:
1040-8428(200111)40:2<187:ATOMMI>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-RISK MELANOMA; CUTANEOUS MELANOMA; STAGE-II; INTERFERON ALFA-2B; PROGNOSTIC FACTORS; SURGICAL ADJUVANT; TRIAL; SURVIVAL; CHEMOTHERAPY; METASTASES;
Keywords:
adjuvant; melanoma; staging; survival; therapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Retsas, S Charing Cross Hosp, Dept Med Oncol, Melanoma Unit, Fulham PalaceRd, London W6 8RF, England Charing Cross Hosp Fulham Palace Rd London England W6 8RF gland
Citazione:
S. Retsas, "Adjuvant therapy of malignant melanoma: is there a choice?", CR R ONC H, 40(2), 2001, pp. 187-193

Abstract

The methodological differences, data interpretation and conclusions of recent studies of adjuvant therapy in high-risk malignant melanoma, are discussed in detail in this communication. Two observations emerge from this analysis:There is as yet no adjuvant treatment that has conclusively been shown to influence overall survival for high-grade primary lesions with or without clinically occult microscopic metastases in regional lymph nodes. With currently available drugs, meaningful benefit is more Rely, if adjuvant treatment is administered on development of clinically apparent regionallymph nodes metastases. The paradox of adjuvant therapy being apparently more effective in more advanced stages of the disease is not unique to melanoma and has been observed in other cancers. This paradox can be explained by the notion that currently available treatments will not eradicate the last malignant phenotype. They may, however, anticipate and frustrate the clinical expression of the next episode of disease activity, in a defined period of time. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/08/20 alle ore 17:02:47